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The threat from new or re-emerging viruses has markedly increased in recent decades due to population growth, urban-ization and the expansion of global travel, facilitating the rapid 
spread of infection during an outbreak1. Over the past four decades, 
we have encountered epidemics from human immunodeficiency 
virus (HIV; 1981–present), severe acute respiratory syndrome 
(SARS; 2002–2004) and Middle East respiratory syndrome (MERS; 
2012–present) coronaviruses, 2009 pandemic influenza H1N1 and 
avian influenza viruses (1996–present), Ebola virus (EBOV) in 
West Africa (2013–2016) and Central Africa (1976–present) and 
Zika virus (ZIKV) in the Americas (2015–2016)2. The initial iden-
tification and containment of these outbreaks were hindered by 
their occurrence in resource-poor settings3 and the unavailability 
of diagnostic assays that could detect a novel, unanticipated viral 
strain. This lack of preparedness underscores the critical need for 
the deployment of effective tools able to rapidly diagnose emerging 
viral infections in febrile patients and to sequence genomes that can 
inform public health interventions to curb transmission.
A high sensitivity of detection is essential for assays that are 
used in clinical and public health settings. PCR-based assays for 
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Metagenomic next-generation sequencing (mNGS), the shotgun sequencing of RNA and DNA from clinical samples, has proved 
useful for broad-spectrum pathogen detection and the genomic surveillance of viral outbreaks. An additional target enrichment 
step is generally needed for high-sensitivity pathogen identification in low-titre infections, yet available methods using PCR 
or capture probes can be limited by high cost, narrow scope of detection, lengthy protocols and/or cross-contamination. Here, 
we developed metagenomic sequencing with spiked primer enrichment (MSSPE), a method for enriching targeted RNA viral 
sequences while simultaneously retaining metagenomic sensitivity for other pathogens. We evaluated MSSPE for 14 different 
viruses, yielding a median tenfold enrichment and mean 47% (±16%) increase in the breadth of genome coverage over mNGS 
alone. Virus detection using MSSPE arboviral or haemorrhagic fever viral panels was comparable in sensitivity to specific PCR, 
demonstrating 95% accuracy for the detection of Zika, Ebola, dengue, chikungunya and yellow fever viruses in plasma sam-
ples from infected patients. Notably, sequences from re-emerging and/or co-infecting viruses that have not been specifically 
targeted a  priori, including Powassan and Usutu, were successfully enriched using MSSPE. MSSPE is simple, low cost, fast 
and deployable on either benchtop or portable nanopore sequencers, making this method directly applicable for diagnostic 
laboratory and field use.
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individual viruses have been widely deployed for diagnostic and 
surveillance applications due to their high sensitivity (1–10 cop-
ies (cp) per ml) and low cost4. However, these assays are limited by 
the requirement for a priori knowledge of the viruses to be targeted 
and the limited number of targets that can be typically multiplexed 
in a single test. The primers used in virus-specific PCR assays also 
invariably suffer from sequence-signature erosion over time due to 
genomic divergence, which occurs rapidly in RNA viruses encoded 
by an error-prone polymerase5.
Metagenomic next-generation sequencing (mNGS) is a promis-
ing candidate approach for broad-spectrum pathogen identification 
in clinical samples, as nearly all potential pathogens (viruses, bac-
teria, fungi and parasites) can be detected by uniquely identifying 
DNA and/or RNA shotgun sequences6,7. This method has been suc-
cessfully applied for the clinical diagnosis of infectious diseases8,9, 
outbreak surveillance10,11 and pathogen discovery12. As it does not 
require a priori targeting of pathogens that may suddenly emerge 
in a new geographic region, such as EBOV in West Africa13, mNGS 
is a potentially useful diagnostic tool for addressing unknown viral 
outbreaks. However, issues related to cost, sequencing depth and 
background contamination14,15 can limit the accuracy of mNGS-
based diagnostics relative to specific PCR testing. In particular, 
although unenriched mNGS using a nanopore sequencer is use-
ful for sequencing known-positive viruses from clinical samples at 
moderate–high titres16,17, it is challenging to use it for the metage-
nomic analysis of clinical samples from patients with low-titre or 
undiagnosed viral infections.
Viral genome sequencing is essential for outbreak management, 
as it enables origin determination and monitoring of viral trans-
mission patterns10. In general, target enrichment of NGS libraries 
is required to obtain sufficient viral genome coverage for phylo-
genetic and molecular clock analyses6. The enrichment of librar-
ies using multiplex PCR of tiled amplicons (tiling multiplex PCR) 
and/or capture probe enrichment has been successfully used for 
the genomic surveillance of EBOV18,19, ZIKV20–22 and yellow fever 
virus (YFV) outbreaks23. Tiling multiplex PCR usually targets only 
a single circulating viral strain at a time; this requires that infec-
tion from that strain be established a priori (generally by previous 
virus-specific PCR testing) and it is thus less practical for viruses 
that exhibit high sequence divergence and/or recombination (for 
example HIV)24, are present as co-infections25 or comprise multiple 
genotypes (for example, hepatitis C virus (HCV), dengue (DENV)). 
Large panels containing millions of probes have been developed to 
capture viral diversity and potentially enrich for hundreds of dif-
ferent viruses26–28, but the relatively high cost, complex protocols 
and prolonged turnaround times (6–24 h for the hybridization 
step alone) needed for efficient capture probe hybridization hinder 
the broad application of this approach. For both methods, cross-
contamination is a serious concern when pooling enriched samples 
together during multiplexing, as high-titre samples commonly con-
taminate low-titre or negative samples on the same sequencing run, 
with ~0.05% cross-contamination reported28.
Here we propose a target enrichment strategy, termed metage-
nomic sequencing with spiked primer enrichment (MSSPE), for 
simple, low-cost (0.10–0.34 USD per sample) enrichment of viral 
reads in sequencing libraries that adds no extra time to existing 
protocols yet retains the breadth of detection afforded by mNGS. 
We previously combined MSSPE with capture probe enrichment to 
recover whole-genome sequences of ZIKV from infected patients 
in Central America and Mexico29, revealing the introduction of the 
virus from Brazil via Honduras and the largely undetected spread 
throughout the region in 2014. In the current study, we expand the 
applications of MSSPE for use in the simultaneous detection and 
genome recovery of a wide range of emerging viruses associated with 
blood-borne infections, including vector-borne (arbovirus; ArboV)-
related febrile illness and haemorrhagic fever. We also validate the 
method on both benchtop Illumina and portable nanopore sequenc-
ing platforms using primary clinical samples from infected patients.
Results
MSSPE for viral pathogen detection. We designed short 
13-nucleotide spiked primers for 15 viruses (14 of which are evalu-
ated in the current study; Fig. 1a,b). The number of primers per 
kilobase (kb) of viral genome reflected the relative diversity of a 
virus species, ranging from 10.8 for measles virus (MeV) to 46.9, 
72.5 and 136.5 for Lassa virus (LASV), HIV and HCV, respectively 
(Supplementary Table 1).
First, we evaluated the enrichment effect of virus-specific 
spiked primers for ZIKV and West Nile virus (WNV) detection on 
Illumina MiSeq. For these experiments, we used either viral culture 
supernatant (ZIKV, DENV, EBOV) or a high-titre clinical sample 
(WNV) spiked at defined concentrations into a negative plasma 
donor matrix. At a spiked primer concentration of 1 μM, the maxi-
mum concentration recommended for specific PCR30, the degree 
of ZIKV enrichment in contrived samples containing ZIKV and 
HCV as an off-target virus was highest (4–6×) at 5:1 and 10:1 molar 
ratios of spiked to random hexamer (RH) primers (Supplementary 
Table 2). There was no or minimal loss of detection sensitivity for 
off-target HCV. Increasing the molar ratio of spiked to RH primers 
to 100:1 from 10:1 did not result in increased enrichment of WNV 
reads using an ArboV spiked primer panel at 1 μM concentration 
(Supplementary Table 3). For spiked primers targeting individual 
viruses, a comparison of concentrations (1, 4 and 10 μM) at a molar 
ratio of 10:1 found that the degree of enrichment peaked at 4 μM 
(Supplementary Table 4).
Next, we tested spiked primer concentrations ranging from 
1 μM to 40–80 μM for the enrichment of ZIKV, DENV and EBOV 
using spiked primer panels for the detection of ArboV, haemor-
rhagic fever viruses (HFV) and 13 viruses combined (CombV). 
The peak performance of the ArboV panel was at a primer concen-
tration of 10–20 μM, yielding a 12-fold enrichment in ZIKV and 
6-fold enrichment in DENV reads (Fig. 2a). Metagenomic detec-
tion of off-target viruses (EBOV) was not impaired. The optimal 
primer concentration for the HFV panel was found to be 20 μM 
(Fig. 2b), yielding a 7× enrichment for EBOV. The CombV panel 
at the optimal 10–20 μM primer concentration yielded 29×, 15× 
and 6× enrichment for ZIKV, DENV and EBOV, respectively (Fig. 
2c). As the degree of enrichment was noted to be higher at lower 
viral titres (Fig. 2a,c), we next tested virus-specific primers (4 μM) 
and expanded panels (10–20 μM) for enrichment of ZIKV, DENV 
and EBOV using optimal concentrations. Notably, the degree of 
fold enrichment of ZIKV, DENV and EBOV using virus-specific 
primers versus larger primer panels (ArboV, HFV and CombV) was 
comparable (Fig. 2d,e).
Next, we evaluated the overall MSSPE enrichment effect across 
14 viruses and 92 paired mNGS runs from both contrived and 
clinical samples at titres ranging from 8 to 112,201 cp ml−1 on the 
Illumina MiSeq platform. For this, and all subsequent sequencing 
experiments, final spiked primer concentrations of 4 μM for indi-
vidual viruses, 10 μM for the ArboV panel and CombV panel and 
20 μM for the HFV panel were used, all mixed with RH primers at 
a ratio of 10:1. The overall median fold enrichment was 10×, with 
6–17× enrichment within the interquartile range (IQR) (Fig. 2f). 
Among contrived samples, a trend of the highest median fold 
enrichment at the lowest titre (median 16× at 10 cp ml−1) was 
observed, with less enrichment (median 7–11×) at titres between 10 
and 10,000 cp ml−1 (Fig. 2g).
The performance of the spiked primer panels was then evaluated 
on the portable MinION nanopore sequencing platform (Oxford 
Nanopore Technologies). Overall levels of ZIKV, EBOV and DENV 
enrichment at viral titres ranging from 10–1,000 cp ml−1 for the 
MinION were comparable to those for the Illumina MiSeq, with 
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Fig. 1 | MSSPE viral primer design and metagenomic sequencing workflow. a, An algorithm for the design of viral spiked primers (SP). Sets of viral 
reference genomes (n = 60–3,571 for each virus) were aligned using MAFFT multiple sequence alignment software49, followed by the partitioning of each 
genome into 300–500-nt overlapping segments. Forward and reverse 13-nt primers were selected and filtered according to specific criteria (rounded 
rectangular box). Unique primer sequences are individually coloured in red, blue, orange and green. Using this algorithm, primers were designed for 15 
RNA viruses. SP panels for ArboV (n = 4), HFV (n = 6) and CombV (n = 13, excluding HCV and JCV SP) were also constructed. b, The metagenomic 
sequencing workflow. MSSPE primers (red) were added (spiked) to a reaction mix containing random primers (blue) during the reverse transcription 
step of cDNA synthesis, without adding to the overall turnaround time for the subsequent transposase-based library amplification with adapter primers 
(brown) and sequencing analysis protocols. The MSSPE workflow is compatible with subsequent enrichment using tiling multiplex PCR and/or capture 
probes (dashed lines). Metagenomic sequence data were analysed for pathogen identification using SURPI (ref. 50; also see Methods). MARV, Marburg 
virus; RVFV, Rift Valley fever virus; HEV, hepatitis E virus; and Tm, melting temperature.
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median enrichment of 13× and 16×, respectively (Supplementary 
Table 5). The use of MSSPE enabled both nanopore- and Illumina-
based metagenomic detection of ZIKV and EBOV down to 
10 cp ml−1, or 2 viral cp per complementary DNA reaction, near 
the limits of detection for virus-specific PCR31,32 (Supplementary 
Table 5). Probit analysis of contrived samples of ZIKV spiked into 
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Fig. 2 | Spiked primer enrichment of viral sequences using MSSPE. a–c, Plots of the fold enrichment achieved for contrived samples containing ZIKV, DENV 
and/or EBOV at defined titres and using RH primers only or SP concentrations ranging from 1 μM to 40–80 μM. The enrichment of ZIKV and DENV using an 
ArboV SP panel (a). The asterisk denotes EBOV as an off-target virus when using the ArboV SP panel. The enrichment of EBOV using a HFV SP panel (b) 
and the enrichment of ZIKV, DENV and EBOV using a CombV SP panel (c). Dashed lines denote 1× or no enrichment. d–h, Box-and-whisker plots of the fold 
enrichment achieved using MSSPE compared to using RH only. The box outlines denote the IQR, the solid line in the box denotes median fold enrichment, 
the dashed line denotes mean (µ) fold enrichment and the whiskers outside of the box extend to the minimum and maximum fold enrichment points. The 
fold enrichment for DENV and ZIKV using virus-specific primers, ArboV panels or CombV panels (d). The fold enrichment for EBOV using virus-specific 
primers, HFV panels or CombV panels (e). The overall fold enrichment, including all 92 pairwise comparisons (with and without MSSPE) of contrived and 
clinical samples (f). The fold enrichment for 65 pairwise comparisons of contrived samples (g). The fold enrichment for 27 pairwise comparisons of clinical 
samples (h). The degree of fold enrichment at <100 cp ml−1 is significantly higher than at other titres (paired two-sided Student’s t test; P = 0.008 between 
groups <100 cp ml−1 and 100–1,000 cp ml−1; P = 0.0002 between groups <100 cp ml−1 and >1,000 cp ml−1).
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donor plasma matrix at serial dilutions of 104 to 1 cp ml−1 using 
the ArboV primer panel and mean sequencing depth of 1,348,588 
(±369,170 s.d.) reads yielded an analytical limit of detection of 
48 cp ml−1 (Supplementary Table 6).
We next evaluated the performance of the ArboV and HFV pan-
els on a portable nanopore sequencer using clinical blood samples 
from 19 patients infected with chikungunya virus (CHIKV; n = 3), 
DENV (n = 4), ZIKV (n = 3, from Brazil), EBOV (n = 3, from the 
Democratic Republic of the Congo (DRC)) and YFV (n = 6, from 
Angola) (Table 1). A median 14× fold enrichment (IQR: 7–17×) 
was observed across different viruses at titres ranging from 15 to 
5,500 cp ml−1 when comparing spiked primers to random primers 
alone. Consistent with the results using contrived samples, clini-
cal samples with lower viral titres of <100 cp ml−1 produced more 
robust enrichment than higher titre samples (P < 0.05 by paired 
t test) (Fig. 2h).
To evaluate the clinical performance of MSSPE testing for the 
detection of ArboV (ZIKV, DENV and CHIKV) and HFV (YFV 
and EBOV) using ArboV and HFV primer panels, respectively, 
we also tested 21 plasma samples from infected patients in paral-
lel with 18 negative control samples on the nanopore sequencer 
(Supplementary Table 7). The overall sensitivity, specificity, posi-
tive predictive value and negative predictive value of the assay were 
95.0%, 94.8%, 92.7% and 96.5%, respectively (Supplementary Table 
8). Three false-positive cases were attributed to barcode misassign-
ments when demultiplexing samples due to a nanopore sequenc-
ing error (Supplementary Table 7). No cross-contamination of 
viral reads was observed in either water or donor plasma matrix 
samples that were processed and sequenced along with contrived 
or clinical samples at estimated titres ranging from 101–107 cp ml−1 
(Supplementary Tables 6 and 7).
Next, we tested whether spiked primers could detect and poten-
tially enrich sequences from emerging flaviviruses in clinical samples 
from infected patients, including Powassan virus (POWV) and 
Usutu virus (USUV) (Table 2). Notably, these viruses had not been 
specifically targeted a priori in the initial spiked primer design. In 
cerebrospinal fluid (CSF) from a patient with tick-borne POWV 
meningoencephalitis, the use of ArboV spiked primers enriched for 
POWV reads by 15× and improved viral genome coverage by 43% 
(Table 2 and Fig. 3d). The alignment of ArboV spiked primers to the 
POWV genome (accession no. NC_003687), tolerating at most one 
mismatch, identified 39 mapping to the genome (Supplementary 
Fig. 1a). As part of an ongoing HIV genomic surveillance study, we 
incidentally detected reads mapping to USUV in a plasma sample 
from an HIV-1-infected patient using mNGS. Experimental testing 
on an Illumina MiSeq at a limited throughput of ~1 million raw 
reads resulted in a failure to detect USUV reads using RH prim-
ers alone, versus detection of six USUV reads using ArboV spiked 
primers (Supplementary Table 9). Follow-up sequencing on an 
Illumina HiSeq at a higher sequencing depth of ~123 million reads 
revealed that the degree of enrichment of USUV reads using the 
ArboV panel was ~7.5× (Table 2), with a corresponding increase 
in genome coverage of 17.5%. Of the spiked primers in the ArboV 
panel, 64 mapped to the USUV genome (Supplementary Fig. 1b).
To assess whether metagenomic detection sensitivity for off-tar-
get DNA viral and non-viral pathogens was retained using MSSPE, 
we evaluated the method using a representative mixture of seven 
organisms developed as a standardized positive control for a clini-
cal metagenomic assay from CSF33. The normalized reads per mil-
lion (RPM) corresponding to each of the seven pathogen types were 
comparable when using the ArboV or HFV spiked primer panel 
versus RH primers alone (Supplementary Table 10). Furthermore, 
the MSSPE method did not enrich reads corresponding to off-target 
viruses associated with laboratory and/or reagent contamination, 
such as murine leukaemia virus34. To determine whether the human 
host background affects the viral enrichment effect by MSSPE, we 
Table 1 | Viral enrichment in clinical blood samples from infected patients using MSSPE
Virusa Titre (cp ml−1) MSSPE 
primerb
Total reads (RH) Viral reads 
(RH)
Virus RPM 
(RH)
Total reads (SP) Viral reads 
(SP)
Virus RPM 
(SP)
Fold change
CHIKV 500 ArboV 2,749,920 16 5.8 2,437,971 100 41 7
CHIKV 210 ArboV 1,505,866 1 0.66 1,737,954 8 4.6 7
CHIKV 15 ArboV 1,530,012 0 0 1,482,002 38 25.6 >25.6
ZIKV 156 ArboV 744,052 0 0 1,018,648 6 6 >6
ZIKV 390 ArboV 1,376,445 2 1.45 1,367,684 12 8.8 6
ZIKV 64 ArboV 1,506,444 2 1.3 1,420,342 38 26.8 20.6
DENV 1,340 ArboV 1,040,773 3 3 1,341,554 24 17.9 6
DENV 5,500 ArboV 1,180,679 683 578.8 2,570,018 6,638 2,582.9 4.5
DENV 78 ArboV 2,277,733 64 28 968,431 388 400.7 14.3
DENV 326 ArboV 3,457,359 174 50.3 2,634,399 2,238 849 16.9
EBOV 35 HFV 1,160,376 1 0.9 1,883,786 40 21.2 23.5
EBOV 78 HFV 2,042,103 0 0 1,083,890 14 14 >14
EBOV 83 HFV 1,775,183 2 1.1 1,816,865 33 18.2 16.5
YFV 68 HFV 1,823,776 24 13.2 2,364,155 508 214.9 16
YFV 2,150 HFV 2,475,206 26 10.5 1,309,068 123 94.6 9
YFV 43 HFV 1,963,780 31 15.8 2,517,501 574 228 14.4
YFV 2,370 HFV 2,456,777 26 10.6 3,689,583 346 93.8 8.8
YFV 79 HFV 1,168,865 19 16.3 1,467,611 550 374.8 23
YFV 228 HFV 1,303,652 5 3.8 2,441,729 63 25.8 6.8
aIndividual samples were barcoded and four to five samples were multiplexed and sequenced on a single nanopore flow cell. bArboV, ArboV SP (10 μM ArboV mixed with RH at a 10:1 ratio); HFV, HFV SP 
(20 μM mixed with RH at a 10:1 ratio).
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compared the proportion of human reads among clinical and con-
trived samples at varying levels of background (25–99.4%). The effi-
ciency of MSSPE enrichment did not decrease with higher levels 
of background, since robust enrichment (5–39×) was still observed 
in CSF or brain tissue samples containing >99% human reads 
(Supplementary Fig. 2).
MSSPE for viral genome sequencing. We hypothesized that the 
increased proportion of viral reads obtained using the MSSPE 
method would improve genome coverage. MSSPE primers were 
used to enrich contrived samples of ZIKV, DENV, EBOV, MeV 
(Edmonston strain), LASV (Josiah strain from Sierra Leone) 
and Crimean–Congo haemorrhagic fever virus (CCHFV, strain 
IbAr10200 from Nigeria) spiked into donor plasma matrix (Fig. 3a; 
Supplementary Tables 11 and 12). On average, 45% (±16% s.d.) 
absolute percentage increases in the breadth of genome coverage 
from deduplicated reads were achieved in contrived samples for 
the non-segmented viruses using MSSPE relative to RH primers 
(Supplementary Table 11). For the segmented CCHFV and LASV 
viruses, MSSPE using virus-specific spiked primers improved 
genome coverage by 69% (±12% s.d.) and 30% (±10% s.d.) for the 
L and S segments of LASV, respectively, and by 58% (±19% s.d.), 
62% (±33% s.d.) and 66% (±21% s.d.) for the L, S and M seg-
ments of CCHFV, respectively (Fig. 3e,f; Supplementary Table 12). 
MSSPE primers were then used to enrich clinical samples of HIV-1 
(divergent and recombinant strains from Cameroon and the DRC; 
Fig. 3b), HCV (genotypes 2, 4 and 6 from California, United States; 
Fig. 3c), ZIKV, CHIKV, YFV, DENV and EBOV (haemorrhagic 
fever patients during the 2014 EBOV Boende outbreak) at low–
moderate viral titres ranging from 43 to 16,512 cp ml−1 (Table 3). For 
these clinical samples, there was a mean 50% (±16% s.d.) increase 
in genome coverage using MSSPE. We also used MSSPE to enrich 
for Jamestown Canyon virus (JCV) in post-mortem brain tissue 
samples from a patient who developed a fatal viral encephalitis fol-
lowing a mosquito bite. Virus-specific enrichment for JCV increased 
the number of viral reads by ~40× versus no enrichment using ZIKV 
primers (Supplementary Table 13). Overall, for the non-segmented 
viruses, the increase in genome coverage using MSSPE across all 
contrived and clinical samples was 47% (±16% s.d.) (calculated 
from all samples in Table 3 and Supplementary Table 11).
Despite robust fold enrichment of 16–55×, no substantial gains 
in genome coverage were observed with clinical samples of ZIKV 
and EBOV at 10 cp ml−1 (Supplementary Table 14), a finding attrib-
uted to insufficient sequencing depth at low viral titres. To evaluate 
the ability of MSSPE to discriminate between different viral sub-
types for the purpose of outbreak tracking, we tested ten clinical 
samples of divergent HIV and HCV viruses with confirmed geno-
types by Sanger sequencing-based assays (Supplementary Table 15). 
All ten samples (100%) were identified as the correct viral subtype 
using MSSPE and genome assembly of mapped reads (average 
depth >30×, ranging from 36× to 6,000×), suggesting that MSSPE 
does not bias the consensus genome assembly.
Table 2 | Detection of untargeted emerging viruses using MSSPE
Virus Clinical 
sample 
type
Primer 
typea
No. of 
preprocessed 
readsb
No. of viral 
reads (RH 
primers)
Viral 
RPM (RH 
primers)
Genome 
coverage 
(RH 
primers) 
(%)
No. 
viral 
reads 
(SP)
Viral 
RPM 
(SP)
Genome 
coverage 
(SP) (%)
Increase in 
coverage 
(%)c
Fold 
change
USUV Serum ArboV SP 122,517,964 114 0.9 5.5 845 6.8 23.0 17.5 7.5
POWV CSF ArboV SP 11,266,014 88 7.8 39.6 1,007 114.6 82.6 43 14.7
aArboV SP, ArboV SP panel at 10 µM concentration and mixed with RH at a 10:1 ratio. bThe same number of Illumina preprocessed reads were analysed from the RH and SP runs for comparison. cAbsolute 
percentage increase from using random primer only (coverage by SP (%) − coverage by RH (%)); a coverage of 40–60% is sufficient for genotypic and phylogenetic inference from partial genome 
assemblies27.
Fig. 3 | Improvements in viral genome coverage using MSSPE. a, Genome coverage of the ZIKV MRC766 (Uganda) strain (mapped to accession no. 
LC002520) at 1,000 cp ml−1 with no enrichment (top) or MSSPE enrichment using ZIKV SP (second from top), an ArboV SP panel (third from top) or a 
CombV SP panel (bottom). With no enrichment, there were 50 reads and 45% coverage; with ZIKV SP, there were 456 reads and 97.6% coverage; with 
ArboV SP, 528 reads and 100% coverage; with CombV SP, there were 254 reads and 93.9% coverage. b, Genome coverage of an HIV-1 Group M, CRF01 
strain (mapped to accession no. KY580709) at 1,000 cp ml−1 with no enrichment (left) or using HIV-1 SP (right). With no enrichment, there were 35 reads 
and 23.2% coverage; with HIV-1 SP, there were 289 reads and 92.8% coverage. c, Genome coverage of an HCV genotype 4 strain (mapped to accession 
no. KM587625) at 10,000 cp ml−1 with no enrichment (left) or using HCV SP (right). With no enrichment, there were 63 reads and 31.5% coverage; 
with HCV SP, there were 686 reads and 80% coverage. d, Genome coverage of a POWV strain identified in CSF from an infected patient with tick-borne 
meningoencephalitis (mapped to accession no. NC_003687) at <1,000 cp ml−1 with no enrichment (left) or using the ArboV SP panel (right). With no 
enrichment, there were 48 reads and 37.1% coverage; with ArboV SP, there were 209 reads and 88.0% coverage. e, Genome coverage of a contrived 
sample of LASV (Josiah strain) spiked into donor plasma matrix at a titre of 10 cp ml−1 (mapped to accession nos. AY628202 and NC_004296) with no 
enrichment (left) or using the HFV SP panel (right). With no enrichment, there were 4 reads and 3.8% coverage; with HFV SP, there were 154 reads and 
67.9% coverage. f, Genome coverage of a contrived sample of CCHFV (mapped to accession nos. AY389508, U39455 and U88410) spiked into donor 
plasma matrix at a titre of 2,500 cp ml−1 with no enrichment (left) or using the HFV SP panel (right). With no enrichment, there were 69 reads and 23.3% 
coverage; with HFV SP, there were 2,636 reads and 100% coverage. g, Genome coverage of a strain from a patient from Mexico with acute ZIKV infection 
during the 2013–2016 outbreak (ZIKV/Homo sapiens/MEX/2016/mex30; mapped to accession no. KX879603) at ~2,000 cp ml−1 with no enrichment 
(top) or enrichment using MSSPE with ZIKV SP (second from top), tiling multiplex PCR (third from top), capture probes (fourth from top, using random 
primers alone) or MSSPE with ZIKV SP followed by capture probes (bottom). With no enrichment, there were 33 reads and 26.5% coverage; with ZIKV SP, 
there were 260 reads and 87.5% coverage; with tiling multiplex PCR, there were 158,243 reads and 88.2% coverage (75.0% ≥10× coverage); with capture 
probes, there were 49,927 reads and 49.1% coverage (29.6% ≥10× coverage); and with ZIKV SP plus capture probes, there were 275,105 reads and 99.8% 
coverage (95.6% ≥10× coverage). The red bars below the coverage plots show nucleotide regions with coverage of ≥10×, at a threshold to minimize the 
inclusion of cross-contaminating reads36. For each graph in a–g, the number of reads is normalized to the total number of viral reads obtained with no 
enrichment. bp, base pairs; L, large segment; M, medium segment, S, small segment.
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Comparison of MSSPE with other target enrichment methods. 
We performed head-to-head comparisons of MSSPE with both 
capture probe35 and tiling multiplex PCR36 methods for the enrich-
ment of viral reads from ZIKV-positive clinical samples at low 
titres (310–28,200 cp ml−1). The degree of improvement in genome 
coverage using MSSPE was comparable to or better than capture 
probe and tiling multiplex PCR methods. However, cross-con-
tamination was observed using tiling multiplex PCR and capture 
probe enrichment, versus no cross-contamination using MSSPE 
(Supplementary Table 16). Furthermore, these two methods 
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generated 80–95% duplicate reads versus ~20% for MSSPE 
(Supplementary Table 17). Tiling multiplex PCR for ZIKV was neg-
ative when testing a contrived ZIKV sample containing the 1947 
prototype Uganda strain MR766, probably due to sequence diver-
gence from the American ZIKV strains from the 2015–2018 out-
break used in the initial multiplex PCR primer design36.
Next, we evaluated the combined performance of MSSPE and 
subsequent tiling multiplex PCR or capture probe enrichment on 
low-titre contrived and clinical ZIKV samples (666–3,340 cp ml−1). 
The use of spiked primers further increased the number of ZIKV 
reads by 6× and corresponding genome coverage by 25–80% (aver-
age 58.5 ± 21.5%), as compared to RH primers alone when used in 
combination with tiling multiplex PCR or capture probe enrichment 
(Supplementary Table 18 and Fig. 3g). Notably, MSSPE was critical 
for ZIKV genome recovery in the two low-titre samples tested by 
tiling multiplex PCR, as multiplex PCR with standard RH priming 
failed to yield a distinct band on gel electrophoresis.
Discussion
In this study, we developed MSSPE as a universal robust target 
enrichment method that is simple, low cost, fast (incurring no extra 
turnaround time), compatible with different library preparation 
protocols (transposon or adapter-ligation based) and deployable on 
benchtop or portable sequencers. We found that the MSSPE method 
produced a median 10× enrichment across 14 different viruses in 
low-titre clinical samples (10–10,000 cp ml−1), improving detection 
sensitivity to 10 cp ml−1 and increasing mean genome coverage by 
47% (±16%), while preserving broad metagenomic sensitivity for 
pathogen detection. Enrichment was possible across a wide range of 
potential targets, from single viruses with varying sequence diversity 
to expanded panels (ArboV and haemorrhagic fever) to the inclu-
sion of a combined panel of 4,792 spiked primers from 13 viral spe-
cies. Notably, MSSPE demonstrated an analytical limit of detection 
of 48 genomic cp ml−1 for ZIKV by probit analysis and compared 
favourably to gold-standard quantitative PCR with reverse tran-
scription (qRT–PCR) testing for the detection of ZIKV, CHIKV, 
DENV, EBOV and YFV in clinical samples from febrile patients 
with viral infection, with analytic performance metrics (sensitivity, 
specificity, positive predictive value and negative predictive value) 
all >92%. Taken together, these results demonstrate the utility of the 
MSSPE method for simultaneous viral diagnosis, genome recovery 
and metagenomic surveillance in laboratory or field settings.
In comparison to other NGS enrichment strategies, such as til-
ing multiplex PCR and capture probe enrichment, we found that 
MSSPE had less biased amplification (~20% duplicate reads ver-
sus 80–95% for the other methods) and less sample cross-con-
tamination. In particular, minimal or no cross-contamination was 
observed with MSSPE when testing contrived and clinical samples 
at virus titres ranging from 10 to 107 cp ml−1. Nevertheless, MSSPE 
was complementary to these other strategies, further increasing the 
yield of viral reads for detection and genome recovery when used 
in combination.
An alternative approach for pathogen enrichment in mNGS 
libraries is the use of a host depletion method. Such methods include 
differential lysis37, the removal of abundant human ribosomal and 
mitochondrial RNA sequences using antibody hybridization or 
depletion of abundant sequences by hybridization (DASH)38 and 
nuclease treatment before extraction39,40. Aside from a post-extrac-
tion DNase step, we did not incorporate host depletion as part of 
MSSPE, given that these methods can be cumbersome, with additional 
Table 3 | Improved viral genome coverage in clinical samples from infected patients using MSSPE
Sequencer Virus Viral titrea 
(cp ml−1)
Primer 
typeb
No. of 
total reads 
analysed
No. of viral 
reads (RH 
primers)c
Genome 
coverage 
(RH 
primers) 
(%)
No. of 
viral 
reads 
(SP)c
Genome 
coverage 
(SP) (%)
Increase in 
coverage 
(%)d
Illumina MiSeq HIV-1 (CRF01) 100 HIV SP 1,892,148 11 12.3 136 62.7 50.4
HIV-1 (CRF01) 10,000 HIV SP 1,507,136 35 22.3 289 90.4 68.1
HIV-1 (CRF01) 10,000 HIV SP 1,656,915 67 43.5 223 76.4 32.9
HIV-1 (URF-0201) 12,589 HIV SP 1,622,623 55 45.1 151 75.1 30.0
HIV-1 (URF-0122) 6,309 HIV SP 1,157,853 11 12.4 81 52.8 40.4
HCV (genotype 2) 16,512 HCV SP 1,728,053 9 11.3 68 50.7 39.4
HCV (genotype 4) 9,846 HCV SP 2,721,805 63 33.3 267 81.3 48.0
HCV (genotype 6) 1,141 HCV SP 1,417,213 17 12.1 81 46.5 34.4
ZIKV (mex9) 814 ArboV SP 846,638 0 0.0 65 40.5 40.5
EBOV (DRC13) 6,440 HFV SP 455, 484 0 0.0 332 73.0 73.0
Oxford Nanopore 
Technology 
MinION
CHIKV (USA) 500 ArboV SP 2,437,971 14 7.6 100 59.7 52.1
DENV (USA) 326 ArboV SP 2,634,399 132 16.1 2,238 89.8 73.7
DENV (USA) 5,500 ArboV SP 1,180,679 683 42.5 3,074 67.6 25.1
YFV (Angola) 68 HFV SP 1,823,776 24 8.7 384 81.6 72.9
YFV (Angola) 43 HFV SP 1,963,780 31 29.4 446 85 55.6
YFV (Angola) 79 HFV SP 1,168,865 19 10.2 437 70 59.8
Mean increase in 
coverage (%)
Mean (s.d.) (n = 16) 50 (±16)
aAbbott m2000 RT–PCR assays were used to estimate the titres of HIV and HCV; viral titres for other viruses were estimated using in-house qRT–PCR assays with standard curve analysis. bHIV SP/HCV 
SP, target virus-specific SP at 4 µM concentration and ArboV SP and HFV SP primer panels at 10 and 20 µM concentrations, respectively, were mixed with RH at a 10:1 ratio. cThe number of reads was 
normalized by equal number of preprocessed reads for comparison. dAbsolute percentage increase from using random primer only (coverage by SP (%) − coverage by RH (%)); coverage of 40–60% is 
sufficient for genotypic and phylogenetic inference from partial genome assemblies27. CRF, HIV circulating recombinant form; URF, HIV unique recombinant form; EBOV (DRC13), Ebola strain from the 2014 
Boende outbreak in the DRC; USA, CHIKV or DENV strain from a traveller returning to the United States from an endemic region; YFV (Angola), YFV strain from the 2015–2016 Angola outbreak.
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steps, and difficult to standardize. Furthermore, host depletion 
methods can bias detection towards specific pathogen types, such as 
the enrichment of bacteria and fungi with cell walls with differential 
lysis37, or encapsidated viruses with pre-extraction nuclease treat-
ment39,40. Host depletion can also be performed at the RNA level 
by the use of non-human primers to bias against abundant human 
host ribosomal and/or mitochondrial RNA41,42. These methods 
have been primarily applied to samples such as cellular lysates and 
throat swabs, which contain significant amounts of human ribo-
somal RNA. For cell-free fluids such as the clinical plasma, CSF and 
serum samples analysed here, the lower proportions of human ribo-
somal RNA can make these methods less effective. The impact of 
non-human primers on the proportion of contaminant sequences 
or metagenomic detection sensitivity for non-viral pathogens 
is also unknown.
To enrich viruses from unknown clinical samples, we developed 
spiked primer panels to detect viruses associated with ArboV infec-
tion or haemorrhagic fever. The use of customized spiked primer 
panels allows RNA viral pathogens associated with a geographic 
region to be targeted (for example, HFV for testing in the DRC and 
ArboV for testing in Brazil). In the future, regional public health 
surveillance data can be leveraged in the composition of real-time 
updated spiked primer panels targeting actively circulating patho-
gens. This is especially important to facilitate the rapid development 
of diagnostic tests for a viral pathogen that is newly introduced to 
a geographic region (for example, EBOV in West Africa, ZIKV in 
Brazil). Of note, we have shown here that detection and enrich-
ment of unexpected re-emerging and/or co-infecting viruses, such 
as USUV and POWV, is possible with MSSPE, even if these viruses 
had not been specifically targeted a priori. Enrichment was due to 
conserved flaviviral primers in the ArboV panel exhibiting inciden-
tal sequence homology to these off-target viruses.
On average, genome recovery for eight different viruses using 
virus-specific spiked primers and expanded panels improved by 
47% (±16%). The minimum threshold that has been proposed for 
completion of a draft viral genome is ≥50% (ref. 43). The percent-
age of samples with ≥50% coverage increased from 15.6% (7 of 
45) using mNGS alone to 86.7% (39 of 45) using MSSPE primers 
(P = 0.0001 by McNemar’s paired two-sided test). Our previously 
published simulations and analyses undertaken in the context of 
ZIKV genomic epidemiology in Central America showed that 
40–60% genome coverage is sufficient for phylogenetic analysis 
and accurate determination of viral lineage (Supplementary Fig. 1 
in ref. 29). Notably, the MSSPE method was effective in the genome 
sequencing of recombinant HIV viruses, in both circulating and 
unknown recombinant forms44, which exhibit sequence divergence 
of up to 35% in the env gene45, as well as multiple HCV genotypes 
and divergent LASV and CCHFV viruses. Robust improvements in 
genome coverage were also observed when testing clinical samples 
of YFV, CHIKV and DENV on the portable nanopore sequencer, 
underscoring the potential utility of MSSPE for the rapid detection 
and monitoring of virus outbreaks.
Our study had some limitations. First, we did not test respira-
tory viruses of outbreak importance, such as coronaviruses, entero-
virus D68 (ref. 16) and influenza viruses. Given the success with all 
RNA viruses tested to date, it is likely that the MSSPE method will 
work in a similar way for additional RNA viruses. Second, we did 
not formally test MSSPE for double-stranded RNA viruses, DNA 
viruses or non-viral pathogens. Third, the degree of enrichment 
by MSSPE varied among the different viruses (range: 4–55×), in a 
similar range to that observed in previous large-panel capture probe 
enrichment studies26–28. The varying enrichment across different 
sample concentrations is probably due to several factors, includ-
ing the number of spiked primers, viral titres in the sample and the 
diversity of viral targets. Fourth, the variable level of enrichment 
and coverage at a given nucleotide position achieved using MSSPE 
might preclude it from high-fidelity viral quasispecies analysis or 
whole-genome assembly at high coverage depth, especially on 
the nanopore sequencer given current sequencing error rates of 
~5–10% (ref. 46). For these applications, MSSPE may be synergistic 
with complementary tiled multiplex PCR or capture probe enrich-
ment approaches, as demonstrated here and previously29.
Methods
Ethics statement. Clinical ZIKV serum samples from Mexico were collected 
as part of the national epidemiological surveillance programme of the Instituto 
Mexicano del Seguro Social (IMSS), a branch of the Ministry of Health, as 
previously described29. Samples and ancillary clinical and epidemiological data 
were de-identified before analysis and are thus considered exempt from human 
subject regulations, with a waiver of informed consent according to 45 CFR 
46.101(b) of the US Department of Health and Human Services. Analysis of whole 
blood samples from patients with EBOV disease was approved by the Ministry 
of Health in the DRC. Patients in the 2014 Boende EBOV outbreak from 13 
August 2014 to 8 September 2014 provided oral consent for study enrolment and 
the collection and analysis of their blood. Consent was obtained at the homes of 
patients or in hospital isolation wards by a team that included staff members of 
the Ministry of Health. Plasma samples from patients with HIV-1 and/or USUV 
infection were provided by the Abbott Global HIV-1 Surveillance Program.  
Briefly, informed consent was obtained for the collection of HIV-1 infected  
blood donations from blood banks in Cameroon and analysis for viral load 
determination and sequencing under protocols approved by local ethics 
committees47. Clinical samples were analysed at the University of California San 
Francisco (UCSF) under protocols approved by the UCSF Institutional Review 
Board (protocol no. 11-05519).
Sample collection. Viral cultures of ZIKV (Uganda strain), DENV (type 1) and 
MS2 bacteriophage were purchased from the American Type Culture Collection 
(ATCC). Ebola cultures (Kikwit strain) in TRIzol LS (Thermo Fisher Scientific) 
were provided by J. Patterson at Texas Biomedical Research Institute. Donor 
plasma matrix consisting of pooled plasma from multiple de-identified blood 
donors that tested negative for infection by blood-borne pathogens,  
including HIV, HBV, HCV and Treponema pallidum, was obtained from Golden 
West Biologicals, Inc.
Clinical ZIKV serum samples were provided by the Central Laboratory of 
Epidemiology (CLE), IMSS in Mexico City, Mexico and Blood Systems Research 
Institute. Forward and reverse primers (ZIKV 1086 and ZIKV 1162c, respectively) 
and carboxyfluorescein (FAM)-labelled probes (ZIKV 1107-FAM) were used 
as previously described48. Clinical CHIKV and DENV samples from febrile 
returning travellers were provided by the California Department of Public Health. 
Clinical Ebola samples collected from patients in the 2014 Boende outbreak were 
provided by INRB in Kinshasa, DRC. Real-time qRT–PCR testing was used for the 
determination of viral titres for ZIKV (refs. 25,48), DENV and EBOV by standard 
curve analysis (Supplementary Table 19). Clinical HIV and hepatitis C plasma 
samples were obtained from the UCSF Clinical Microbiology Laboratory (San 
Francisco, USA). Clinical samples from HIV-infected patients in Cameroon were 
provided by the Universities of Yaounde, Bamenda and Montanges in Cameroon 
and Abbott Laboratories, Inc. Clinical yellow fever samples collected from patients 
in the 2015–2016 yellow fever outbreak in Angola were provided by the Angolan 
National Institute of Public Health. The CSF sample from a patient with POWV 
meningoencephalitis was provided by Boston Children’s Hospital. Post-mortem 
brain biopsy tissue from a patient who died of JCV encephalitis was provided by 
Massachussetts General Hospital. The positive control of seven organisms was 
obtained from the UCSF Clinical Microbiology Laboratory. A representative 
mixture of seven organisms included an RNA virus (HIV), a DNA virus 
(cytomegalovirus), a Gram-positive bacterium (Streptococcus agalactiae), a Gram-
negative bacterium (Klebsiella pneumoniae), a yeast (Cryptococcus neoformans), a 
mould (Aspergillus niger) and a parasite (Toxoplasma gondii).
MSSPE viral spiked primer design. We sought to develop a general method for 
combining metagenomic viral detection with enrichment and genome recovery 
from clinical samples. We required that the method should: be applicable for 
targeted viruses with varying numbers of reference genomes/genome segments in 
the database (for example, from 60 to 3,571) (Fig. 1a); preserve broad metagenomic 
sensitivity for comprehensive detection of off-target viruses and/or viral co-
infections; not impact turnaround times for sample processing; enrich mNGS 
libraries sufficiently to allow robust viral genome recovery from low-titre clinical 
samples. Specifically, we designed an automated computational algorithm that took 
an arbitrary set of reference genomes as an input and constructed a minimal panel 
of short, 13-nucleotide spiked primers to cover these genomes (Fig. 1a), which 
were to be added during the cDNA synthesis (reverse transcription) step of mNGS 
library preparation (Fig. 1b).
To design specific spiked primers for a virus, multiple sequence alignment 
of complete viral genomes (downloaded from the National Center for 
Biotechnology Information (NCBI) GenBank nucleotide database as of 
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September 2017) was performed using multiple alignment using fast Fourier 
transform (MAFFT) (v.7.388) at default parameters (algorithm = “Auto”, scoring 
matrix = “200PAM/k = 2”, gap open penalty = 1.53, off-set value = 0.123)49. An 
in-house bioinformatics pipeline named MSSPE-design (v.1.0) was developed on 
an Ubuntu Linux computational server for the automated design of spiked primers. 
Briefly, the multiple sequence alignment-aligned genomes were partitioned into 
overlapping 500-nucleotide segments with 250-nucleotide overlap using PYFASTA 
(http://pypi.python.org/pypi/pyfasta/). Forward or reverse 13-nucleotide primers 
were selected from 50-nucleotide regions at the ends of each segment by iteratively 
ranking candidate 13mer (kmer) sequences in reverse order by frequency, selecting 
the top kmer shared by the most segments and not containing any ambiguous 
nucleotides and then removing segments sharing that 13mer before repeating the 
process on the remaining segments. To decrease overall spiked primer costs, the 
iterations were repeated until the number of remaining segments containing a 
shared kmer was below a predesignated threshold (ranging from n = 1 for viruses 
with only a limited number of genomes/genome segments, such as CCHFV, to 
n = 10 for viruses comprising thousands of genomes and multiple genotypes, such 
as DENV). Spiked primers were filtered by the removal of primers with melting 
temperatures greater than 2 s.d. from the mean or that were predicted to self-
dimerize or cross-dimerize with a ΔG value (standard free energy of DNA duplex 
formation) equal to or more negative than −9 kcal mol−1.
Spiked primers were synthesized by Integrated DNA Technologies Inc.  
Forward or reverse spiked primer oligonucleotides targeting individual viruses 
were synthesized on a 10 nmol scale in 96-well plates with standard desalting 
and 6 nmol of each individual oligonucleotide was mixed and then resuspended 
to a final volume of 500 μl in IDTE pH 8.0. Spiked primer panels (ArboV, HFV 
and CombV) were designed by mixing the spiked primers for each individual 
virus in equimolar ratios and then diluting with Tris–EDTA buffer to the desired 
concentration. The estimated cost per sample for 1 million reads using the Illumina 
MiSeq is approximately US$100 for random metagenomic sequencing. For  
tenfold more viral reads, approximately 10–20 million raw sequencing reads are 
needed, with an estimated cost of US$250 per sample using an Illumina HiSeq 
platform. By comparison, the MSSPE approach can obtain 10× average viral 
enrichment at low incremental costs of US$0.06–US$0.08 per sample using 
individual virus-specific primers or US$0.17–US$0.34 using spiked primer panels 
(Supplementary Table 20).
Construction of metagenomic sequencing libraries. To minimize sample and 
exogenous laboratory cross-contamination during library preparation, strict 
measures were implemented, including unidirectional workflow, separation 
of pre-PCR and post-PCR workspaces using different rooms and rigorous 
decontamination of biosafety cabinets and work benches using 10% bleach  
and/or 70% ethanol. Potential contamination was monitored by the processing  
of negative water and donor plasma matrix controls in parallel with samples  
for a subset of runs.
For the preparation of metagenomic sequencing libraries, viral RNA was 
first extracted from 400 µl of contrived or clinical patient samples using the EZ1 
Advanced XL BioRobot and EZ1 Virus Mini Kit (Qiagen), with the exception 
of EBOV RNA, which was extracted manually in the viral haemorrhagic fever 
reference laboratory in INRB, Kinshasa using the Direct-zol RNA MiniPrep Kit 
(Zymo Research). Final RNA was eluted in 60 μl AVE buffer. 25 μl of nucleic acid 
extract was treated with DNase (3 μl Turbo DNase, 1 μl Baseline, 5 μl Turbo buffer 
and 16 μl nuclease-free water) and incubated on an Eppendorf ThermoMixer at 
37 °C, 600 r.p.m. for 30 min. The Zymo RNA Clean and Concentrator kit (Zymo 
Research) was used to clean up DNase-treated RNA and the final RNA was eluted 
in 32 μl water. The RNA was then mixed with RH alone (1 μM) or spiked primer 
plus RH in a 10:1 ratio of spiked primer to RH and heated to 65 °C for 5 min. 
The reverse transcription master mix (10 μl SuperScript III buffer, 5 μl dNTP 
(12.5 mM), 2.5 μl DTT (0.1 M), 1 μl SuperScript III enzyme) was added to each 
sample and incubated at 25 °C for 5 min, followed by 42 °C for 30 min and 94 °C 
for 2 min. After cooling to 10 °C, a second-strand synthesis master mix (3.7 μl 
Sequenase buffer, 0.225 μl Sequenase enzyme and 1.1 μl water) was added to each 
reaction, followed by a slow 2 min ramp to 37 °C and an 8-min incubation. The 
resulting cDNA was cleaned up using the Zymo DNA Clean and Concentrator kit 
(Zymo Research), with the addition of 10 μl linear acrylamide to each sample, and 
eluted in 7.5 μl water. Using the Illumina Nextera XT kit, 2.5 μl sample cDNA was 
incubated at 55 °C for 5 min in tagmentation mix (10 μl TD buffer and 5 μl ATM 
enzyme) and immediately neutralized with 2.5 μl NT buffer. 12.5 μl tagmented 
DNA was then transferred to the reaction tube containing indexing mix (7.5 μl 
Nextera XT PCR master mix, 2.5 μl N-7XX primer and 2.5 μl S-5XX primer 
from Illumina) for the barcoding of individual samples. PCR amplification was 
then performed using the following conditions: an initial denaturation step of 
95 °C for 30 s, followed by 16 cycles of denaturation (95 °C for 10 s), annealing 
(55 °C for 30 s) and extension (72 °C for 30 s), with a final extension at 72 °C for 
5 min. After PCR, 3 μl of PCR product was analysed by 2% gel electrophoresis 
to check for library size and band intensity. If no band or only a very faint band 
was observed on the gel, another round of recovery PCR was performed. For 
recovery PCR, the library was washed using 0.9X AMPure XT beads (Beckman 
Coulter) and 5 μl clean library was mixed with 45 μl master mix (10 μl buffer, 2.5 μl 
10 μM Nextera general primers (forward: 5′-AATGATACGGCGACCACCGA-3′; 
reverse: 5′-CAAGCAGAAGACGGCATACG-3′), 1 μl dNTP, 0.5 μl Phusion DNA 
polymerase enzyme and 31 μl water), followed by a 95 °C incubation for 30 s and 
10 cycles of PCR (95 °C for 30 s denaturation, 60 °C for 30 s annealing and 72 °C for 
30 s extension), with a final extension at 72 °C for 5 min. The final cDNA library 
was eluted in 20 μl EB buffer after a wash step using 0.9X AMPure beads.
Metagenomic sequencing. The cDNA libraries were quantified using a Qubit 
fluorometer (Thermo Fisher Scientific) and the sizes of the libraries were measured 
using an Agilent Bioanalyzer (Agilent Technologies). Up to 16 samples were mixed 
and pooled together and the final multiplexed library was quantified again using 
a Qubit fluorometer. Illumina sequencing was performed on a MiSeq instrument 
using 150-nucleotide single-end runs according to the manufacturer’s protocol. For 
nanopore sequencing, three to five individually barcoded cDNA Nextera libraries 
were mixed in equimolar amounts, with the final mix containing 200–800 ng 
of DNA. The DNA was then end-repaired and ligated with adapter and motor 
proteins using the 1D Ligation Sequencing Kit (Oxford Nanopore Technologies). 
For nanopore sequencing, metagenomic libraries were run on R9.4 or R9.5 flow 
cells, using either a MinION MK1B or GridION X5 instrument (Oxford Nanopore 
Technologies). Up to five barcoded sample libraries were prepared using the 1D 
Ligation Sequencing Kit (Oxford Nanopore Technologies), quantified and pooled 
together in an identical fashion to the Illumina Nextera libraries and loaded on a 
single flow cell for sequencing.
Capture probe enrichment for ZIKV samples. The xGen Lockdown Kit (IDT 
Technologies) was used for capture probe enrichment of ZIKV. Briefly, barcoded 
amplified cDNA libraries corresponding to each sample were mixed in equimolar 
proportions to generate a 500-ng pooled library. The pooled library was then 
added to a hybridization mix containing ZIKV xGen Lockdown probes and the 
hybridization reaction was performed by incubation at 65 °C for 16 h, followed 
by streptavidin bead capture for 45 min. Beads containing captured cDNA 
were resuspended in an amplification reaction mix (25 μl KAPA HiFi HotStart 
ReadyMix, 1.25 μl xGen primer and 3.75 μl water) and post-capture PCR was 
performed (98 °C for 45 s, followed by 10 cycles of denaturing (98 °C for 15 s), 
annealing (60 °C for 30 s) and extension (72 °C for 30 s), with a final extension at 
72 °C for 1 min). PCR amplicons were purified using a 1.5× volume of AMPure XP 
beads and finally eluted in 20 μl EB buffer. Purified PCR products were analysed 
by 2% gel electrophoresis to check the library size and DNA concentration was 
estimated using a Qubit fluorometer. The capture probe enriched library was run 
on an Illumina MiSeq instrument using 150-nucleotide single-end runs according 
to the manufacturer’s protocol.
Tiling multiplex PCR enrichment for ZIKV. Tiling multiplex PCR for ZIKV 
enrichment was performed according to the Primal protocol described in ref. 36,  
except for libraries prepared using both MSSPE and tiling multiplex PCR, for 
which an AMPure bead wash of 1.2× was performed immediately after cDNA 
synthesis (before adding multiplexed primers) to remove residual ZIKV MSSPE 
primers (4 μM) that had been added during the reverse transcription step. After 
visualization of a PCR band of the expected size (400 nucleotides) by 2% gel 
electrophoresis, barcoded sequencing libraries were prepared using the NEBNext 
Ultra II DNA Library Preparation Kit (New England BioLabs, Inc.) and sequenced 
on an Illumina MiSeq instrument using 250-nucleotide paired-end runs according 
to the manufacturer’s protocol
Bioinformatics pipelines for viral detection and reference genome alignment. 
Sequencing data from Illumina MiSeq or HiSeq instruments were analysed for 
viruses using the sequence-based ultra-rapid pathogen identification (SURPI+ 
v.1.0) computational pipeline (UCSF), a modified version of a previously published 
bioinformatics analysis pipeline for pathogen identification from mNGS sequence 
data33,50. Specifically, the SURPI+ pipeline modifications include: updated reference 
databases based on the NCBI nucleotide database (March 2015 build); a filtering 
algorithm for the exclusion of false-positive hits from database misannotations; 
and taxonomic classification for species-level identification. After SURPI+ 
identification of viral reads, viral reads were trimmed by 13 nucleotides at the 
5′ and 3′ end to remove the spiked primers before mapping to the most closely 
matched reference genomes and visualization using SURPI+33,50 or Geneious 
11.1.3 (ref. 51). Duplicate viral reads were removed using Prinseq (v.0.20.4)52 with 
the “-12345” parameter before genome mapping and assembly. To estimate the 
percentage of human reads (human background) in clinical samples or contrived 
samples spiked into donor plasma matrix, Illumina preprocessed reads were 
aligned to human reference genome hg38 (accession no. GRCh38.p12) and the 
proportion of human reads was determined using the SURPI+ pipeline.
Nanopore sequencing was run on either a Mk1b MinION or GridION 
instrument. Nanopore raw fast5 files were basecalled using Albacore (MinION) 
or Guppy (GridION) in real-time mode without polishing. For virus detection 
from nanopore reads, we used a pipeline developed in-house called SURPI real 
time (SURPIrt v.1.0). Briefly, for multiplexed samples, FASTQ files were first 
computationally separated by barcode, followed by preprocessing for trimming of 
adapters and low-complexity sequences. After partitioning the first 450 nucleotides 
NATuRE MICROBIOLOGY | VOL 5 | MARCH 2020 | 443–454 | www.nature.com/naturemicrobiology452
ArticlesNature Microbiology
of the preprocessed nanopore read into three 150-nucleotide segments, viral reads 
were identified using Bowtie 2 (ref. 53) alignment with a minimum alignment score 
cut-off of 100. Filtering and taxonomic classification algorithms were then applied 
as described above. Viral reads were trimmed by 13 nucleotides at the 5′ and 3′ 
end to remove any spiked primers and PCR duplicate reads were removed before 
mapping to the most closely matched reference genome using GraphMap (v.0.5.2)54 
and visualization using Geneious (v.11.1.13)51.
Quantification and statistical analysis. For Illumina sequencing, the RPM metric 
was calculated as the number of viral species-specific reads divided by the number 
of preprocessed reads (after trimming, low-quality filtering and low-complexity 
filtering of raw reads) × 1 million. For nanopore sequencing, the RPM was 
calculated as the number of viral species-specific reads divided by the number of 
basecalled reads × 1 million. Enrichment was defined as the RPM obtained for a 
target virus using MSSPE divided by the RPM obtained using RH priming only. 
The median fold change and IQR are given for non-normally distributed data. The 
percentage increase in genome coverage is the genome coverage obtained using RH 
alone subtracted from that obtained using MSSPE. McNemar’s paired test was used 
to compare two proportions for paired conditions (before and after using MSSPE), 
with a P value of less than 0.05 considered statistically significant. A paired t test 
was used to compare the mean fold enrichment between groups, with a P value  
of less than 0.05 considered statistically significant. Probit analysis for 
determination of limits of detection was performed using StatPlus software 
(AnalystSoft, Inc., v.6.2.30).
For the comparison between the use of spiked primers and random primers 
only, normalization across barcoded runs was performed by: randomly selecting a 
subset of preprocessed reads, with the size fixed to the run with the fewest number 
of reads; determining the number of viral reads within each equally sized subset of 
preprocessed reads; and tabulating the viral reads for each subset and using them 
for downstream genome assembly.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
Sequence data were deposited in the NCBI Sequence Read Archive after removal 
of human genomic reads (NCBI BioProject accession no. PRJNA578816, umbrella 
BioProject accession no. PRJNA171119). The data that support the findings of the 
study are available from the corresponding author on reasonable request. MSSPE 
primer sequences tested in this study are provided in Supplementary Table 21. 
Source data for Fig. 2 are presented with this paper.
Code availability
SURPI+, SURPIrt and MSSPE-design have been deposited on Github and are 
available for download for research use only at https://github.com/chiulab/SURPI-
plus-dist, https://github.com/chiulab/SURPIrt-dist and https://github.com/chiulab/
MSSPE-design, respectively.
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nanopore sequencing, up to five individually barcoded cDNA Nextera libraries were pooled together (equal DNA amount to make 200 ng 
– 1 ug of input DNA), then end-repaired and ligated with adapter and motor proteins using the 1D Ligation Sequencing Kit (Oxford 
Nanopore Technologies). Metagenomic libraries for nanopore sequencing were run on R9.4 or R9.5 flow cells, using either a MinION 
MK1B or GridION X5 instrument (Oxford Nanopore Technologies). Nanopore raw FAST5 files were collected and basecalled using 
Albacore (MinION) or Guppy (GridION) in real-time mode without polishing. Illumina data was collected on an Illumina HiSeq or MiSeq 
instrument. Details were included in the Method section of the paper.
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